Navigation Links
New Study Demonstrates Clinical Validity of EarlyCDT-Lung™
Date:8/5/2010

tumor antigens to detect the presence of immuno-biomarkers produced in the form of autoantibodies by the patient's immune system. Elevation of any one of six immuno-biomarkers (autoantibodies) above a predetermined cutoff value suggests that a tumor might be present. This simple blood test aids in risk assessment and the early detection of lung cancer in high-risk patient populations. The key advantage of the test is its ability to detect cancer earlier, and with higher specificity, than spiral-CT which is the standard diagnostic imaging test used for these patients today. EarlyCDT-Lung is priced below a CT scan and as a simple blood test, eliminates radiation exposure from imaging screening techniques. High-risk individuals such as long-term smokers and ex-smokers between the ages of 40 and 75 and individuals with other risk factors such as environmental exposures and extensive exposure to secondary smoke are candidates for the test. Further research to investigate the most beneficial clinical use of the test (i.e., as a first test leading to further testing for those positive, or as a test providing further information to those who already have a CT identified nodule) is currently being finalized. EarlyCDT-Lung is CLIA (Clinical Laboratory Improvement Act) regulated. Other tests for breast, ovarian, esophagogastric, colon and liver cancers are planned. For more information about Oncimmune's EarlyCDT-Lung, visit: http://www.oncimmune.com.  

About Oncimmune LLC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through
'/>"/>

SOURCE Oncimmune (USA) LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
2. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
3. DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Study measures single-molecule machines in action
8. Recent Study Reports Reveals that HGH May Aid Performance
9. Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
10. Depth charge: Using atomic force microscopy to study subsurface structures
11. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index ... , in particular, drug/device combinations. The current system received a score of 0 (range ... Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... , ANNAPOLIS, Md., July 31 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, today announced that, ... of 2-year, 10% unsecured senior convertible notes ("Notes") and common ... $19.3 million. , , In connection with ...
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... , TOKYO, July 31 R-Tech Ueno, Ltd. ... meeting of the board of directors held on the day and ... The company intends to actively strengthen R&D in the ophthalmologic & ... relevant affiliation, etc. with external entities. , , ...
Cached Biology Technology:PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... The 2009 American Society for Microbiology Public ... reporters Michael Berens and Ken Armstrong for their ... (MRSA) in Washington State hospitals. The series, entitled ... the spread of epidemics such as MRSA infection ...
... diseases that starve eye tissue and nerves of oxygen ... researchers at Oak Ridge National Laboratory, the University of ... technique uses a new class of smart prosthetic implants ... oxygen because of restricted blood flow. This condition occurs ...
... high among people born in Scotland or Ireland compared with ... Research, conducted by the University of Edinburgh and the Office ... but living in England and Wales had similar ... The findings showed too that people born in parts of ...
Cached Biology News:Seattle Times reporters win ASM public communications award 2ORNL, Southern Cal set sights on preventing blindness 2Scots and Irish at greater risk of drink-related death, study shows 2
... is a post-translational modification that plays ... including immune regulation, inflammation, cell-to-cell adhesion, ... developed two lectin based Glycoprotein Isolation ... Germ Agglutinin (WGA), that allow isolation ...
... maleimide activated carrier proteins to simplify ... Maleimide Activated Carrier Proteins are commonly ... with a heterobifunctional cross-linker (Sulfo-SMCC). This ... carrier protein. Thus allowing the ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, nontreated polystyrene...
Biology Products: